A new treatment for bipolar mania cleared a major clinical trial

Johnson & Johnson's Caplyta met its main goal in a late-stage study of bipolar mania, offering hope for a condition with few good options. The drug, already used for schizophrenia and bipolar depression, could become a new tool for the manic highs that derail lives. More options mean more people finding the one that works.